/PRNewswire/ AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative.
/PRNewswire/ AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative.
(MENAFN - Baystreet.ca) AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) rose Monday on the results of research into its pain medication. The Redwood City, Calif.-based AcelRx Pharmaceuticals, earlier during the month, announced an investigator-initiated study to assess the perioperative use of Dsuvia (sufentanil sublingual tablet) for same-day surgical procedures in patients on buprenorphine therapy for opioid-use disorder or chronic pain management. The principal investigator, Dr. Naum Shaparin, is the Interim Chair of the Department of Anesthesiology and Director of the Multidisciplinary Pain Program at Montefiore Medical Center and Professor of Anesthesiology at Albert Einstein College of Medicine. The study was to evaluate the efficacy and safety of Dsuvia for perioperative management of surgical pain in patients on buprenorphine treatment.